For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium also includes the Zacks Style Scores.What are the Zacks Style Scores?The Zacks Style Sc ...

Lantheus Holdings, Inc. (NASDAQ:LNTH) Q4 2023 Earnings Conference Call February 22, 2024 8:00 AM ET Company Participants Mark Kinarney - VP, IR Mary Anne Heino - CEO Brian Markison - Chairman Paul Blanchfield - President Bob Marshall - CFO Conference Call Participants Anthony Petrone - Mizuho Group Roanna Ruiz - Leerink Partners LLC Richard Newitter - Truist Securities Yuan Zhi - B. Riley Matt Taylor - Jefferies Justin Walsh - Jones Trading Andy Hsieh - William Blair Larry Solow - CJS Securities Kemp Dolliv ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _______________________________________________________________ FORM 10-K _______________________________________________________________ (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File N ...

Lantheus Holdings, Inc. (NASDAQ:LNTH) Q3 2023 Earnings Conference Call November 2, 2023 8:00 AM ET Company Participants Mark Kinarney - Vice President of Investor Relations Mary Anne Heino - Chief Executive Officer Paul Blanchfield - President Bob Marshall - Chief Financial Officer Conference Call Participants Roanna Ruiz - Leerink Richard Newitter - Truist Securities Matt Taylor - Jefferies Anthony Petrone - Mizuho Group Andy Hsieh - William Blair Justin Walsh - JonesTrading Larry Solow - CJS Securities Yu ...

Investing in the Business K E Y D R I V E R S Investment in ERP implementation, as well as in risk management and employee engagement AVAILABLE REVOLVING CREDIT $14.6 INCREASE $87.5 $102.1 $ 3Q 2022 350.0 3Q 2023 © 2023 Lantheus. All rights reserved. 17 1. On a forward-looking basis, the Company does not provide GAAP income per common share guidance or a reconciliation of adjusted fully diluted EPS to GAAP income per common share because the Company is unable to predict with reasonable certainty business de ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36569 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) | Delaware | 35-2318913 ...

Lantheus Holdings, Inc. (NASDAQ:LNTH) Q2 2023 Earnings Conference Call August 3, 2023 8:00 AM ET Company Participants Mark Kinarney - Vice President of Investor Relations Mary Anne Heino - Chief Executive Officer Paul Blanchfield - President Bob Marshall - Chief Financial Officer Conference Call Participants Roanna Ruiz - Leerink Partners Yuan Zhi - B. Riley Richard Newitter - Truist Securities Matt Taylor - Jeffries Anthony Petrone - Mizuho Americas Justin Walsh - Jones Trading Larry Solow - CJS David Turk ...

© 2023 Lantheus. All rights reserved. 22 Condensed Consolidated Statement of Operations – 2Q 2023 1. Internal analyses; 2. DRG Echo Monthly Monitor; 3. See slide 28 for reconciliations of GAAP to non-GAAP financials; certain amounts may be subject to rounding. (in thousands – unaudited) 13,092 354 © 2023 Lantheus. All rights reserved. Seasoned and Experienced with a Strong Track Record of Value Creation 1. CONDOR pivotal registrational study evaluated as a secondary endpoint change in intended patient manag ...

Table of Contents FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36569 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) | Delaware | 35-2318913 | | - ...

Financial Data and Key Metrics Changes - In Q1 2023, the company reported record revenues of $300 million, an increase of $91.9 million or 44% year-over-year [39] - Adjusted earnings per share (EPS) for the quarter were $1.47, reflecting an increase of $0.50 or 51.3% compared to the prior year [39] - Gross profit margin improved to 68.6%, up 165 basis points from Q1 2022, driven by favorable volume and product mix [32] Business Line Data and Key Metrics Changes - The radiopharmaceutical oncology category generated $196.2 million in sales, significantly up year-over-year, primarily due to the growth of PYLARIFY [30] - Sales of PYLARIFY reached $195.5 million, representing a 110% increase year-over-year and 22% sequential growth [33] - DEFINITY sales were $68.8 million, an 18% increase from the prior year, benefiting from increased patient office visits [36] Market Data and Key Metrics Changes - The global radiopharmaceutical market is projected to grow from $6 billion in 2021 to over $35 billion by 2031, driven by new approvals and increasing patient diagnoses [24] - The company holds approximately 75% market share in the PSMA PET imaging market, indicating strong competitive positioning [115] Company Strategy and Development Direction - The company is focused on expanding its commercial portfolio and pipeline, including the recent acquisition of Cerveau Technologies for MK-6240, aimed at Alzheimer's diagnostics [8][19] - The partnership with POINT Biopharma is expected to lead to the launch of two additional oncology radiotherapeutics in the coming years [25] - The company aims to leverage its manufacturing and supply chain capabilities to drive growth in both therapeutics and diagnostics within the radiopharmaceutical sector [118] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future of the radiopharmaceutical industry, highlighting the company's unique position to lead and innovate [12] - The FDA's Fast Track designation for PNT2002 is expected to facilitate quicker development and review processes, enhancing the company's growth prospects in treating metastatic prostate cancer [6][20] - The anticipated top-line data readout for the PNT2002 SPLASH trial in the second half of 2023 is viewed as a significant milestone [21] Other Important Information - The company has a strong liquidity position with cash and cash equivalents of $470.9 million and access to a $350 million undrawn bank revolver [46] - The full-year revenue guidance has been updated to a range of $1.23 billion to $1.27 billion, reflecting strong performance in Q1 [72] Q&A Session All Questions and Answers Question: How large are the PMFs and how impactful to volumes can those sites be? - The company continues to expand its PMF network to enhance flexibility and customer experience, although specific numbers of hospitals in the network were not disclosed [52][54] Question: Is DEFINITY expected to sustain double-digit growth? - Management indicated that DEFINITY's growth is supported by returning patient volumes and improved hospital efficiencies, with expectations for continued growth [86][107] Question: What is the value proposition of PYLARIFY versus competitors? - PYLARIFY holds a significant market share due to its superior imaging capabilities and is preferred by healthcare professionals for its effectiveness in prostate cancer imaging [115] Question: What are the plans for PNT2003 and its market opportunity? - PNT2003 is on track for development, with an estimated market opportunity of approximately $800 million [156] Question: What is the impact of the Fast Track designation for PNT2002? - The Fast Track designation allows for more frequent interactions with the FDA, facilitating a more efficient submission process for the NDA [135][161]